Search
Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated)
go.drugbank.com/drugs/DB11044ApprovedWithdrawnThe influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. … Upon re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus
Mixtures: Medical Provider Single Use EZ Flu Shot Afluria 2016-2017, Medical Provider Single Use EZ Flu Shot Fluvirin 2016-2017Tideglusib
go.drugbank.com/drugs/DB12129ApprovedInvestigationalWithdrawn[A31601] Tideglusib is being developed by the Spanish pharmaceutic company Zeltia group and its current status is withdrawn for the treatment of Alzheimer's disease as of 2012. … It is reported to be a potent anti-inflammatory and neuroprotective that is a non-ATP competitive inhibitor of glycogen synthase kinase 3 (GSK-3).
Olezarsen
go.drugbank.com/drugs/DB18728ApprovedInvestigationalOlezarsen is an antisense oligonucleotide that targets the messenger RNA (mRNA) for apolipoprotein C-III (APOC3, apoC-III),[L52033] which is a key regulator of triglyceride levels in plasma, in the liver … [L52028] It is also being investigated for the treatment of hyperlipidemia.[A264898,A264903]
Medium-chain triglycerides
go.drugbank.com/drugs/DB13959ApprovedInvestigationalMedium-chain triglycerides (MCTs) are triglycerides made up of a glycerol backbone and three fatty acids with an aliphatic tail of six to 12 carbon atoms. … MCTs are found in natural foods, such as coconut oil, palm kernel oil, and raw coconut meat.
Plozasiran
go.drugbank.com/drugs/DB18997ApprovedInvestigationalPlozasiran (ARO-APOC3) is a small interfering RNA (siRNA) that degrades apolipoprotein C-III (apoC-III) mRNA by RNA interference.
Olive oil
go.drugbank.com/drugs/DB09567ApprovedInvestigationalUsed as a source of fatty acids in total parenteral nutrition and as an additive in some cosmetic products [FDA Label].
Remibrutinib
go.drugbank.com/drugs/DB16852ApprovedInvestigationalRemibrutinib is a selective Bruton's tyrosine kinase inhibitor. The FDA approved remibrutinib on September 30, 2025 as the only oral, targeted treatment for chronic spontaneous urticaria. … [A274501, L54101] Remibrutinib has also been investigated in other inflammatory conditions,[A274511] such as autoimmune encephalomyelitis [A274501] and Sjögren's syndrome.[A274521]
Quizartinib
go.drugbank.com/drugs/DB12874ApprovedInvestigationalQuizartinib is an oral and potent fms-like tyrosine kinase 3 (FLT3) inhibitor and it is the first drug developed specifically targeting FLT3, as other agents with FLT3 inhibition activities were investigated … [A260651] Therefore, quizartinib is proven to be a beneficial addition to the current AML treatment regimen, although serious side effects such as QT prolongation necessitates further research to optimize
Celecoxib
go.drugbank.com/drugs/DB00482ApprovedInvestigationalCelecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is a nonsteroidal anti-inflammatory drug (NSAID) which is known for its decreased risk of causing gastrointestinal bleeding compared to other … [A181532] It is marketed by Pfizer under the brand name Celebrex, and was initially granted FDA approval in 1998.
Categories: Genito Urinary System and Sex HormonesClenbuterol
go.drugbank.com/drugs/DB01407ApprovedInvestigationalVet approvedIt is used as a bronchodilator in asthma.
Categories: Adrenergics for Systemic Use